

Insulin resistance is increased in adult patients with dermatomyositis

Diego Sales de Oliveira¹, Marilda Silva Guimarães¹, Samuel Katsuyuki Shinjo¹

¹ Universidade de São Paulo, Faculdade de Medicina (FMUSP), Division of Rheumatology, São Paulo, SP, Brasil

OBJECTIVE: To evaluate insulinemia in glucocorticoid naïve patients with dermatomyositis and to evaluate insulin resistance using the homeostatic model assessment of insulin resistance (HOMA2-IR).

METHODS: This cross-sectional study included 25 dermatomyositis, non-diabetic glucocorticoid naïve patients. The control group consisted of 50 volunteers matched for age, gender, ethnicity, weight and height. The HOMA2-IR index was calculated from baseline insulin and glucose data. The International Myositis Assessment & Clinical Studies Group (IMACS) parameters were used to evaluate disease status.

RESULTS: Mean age of the patients was 43.5 years and these were predominantly females. Patients had low disease activity according to IMACS parameters. Higher body mass index and waist circumference were observed in the dermatomyositis group compared to the control group. Insulin level and HOMA2-IR were also higher in patients with dermatomyositis. Moreover, analyzing dermatomyositis alone, the HOMA2-IR index correlated positively with weight, body mass index and waist circumference and was independent on disease status parameters.

CONCLUSIONS: Patients with dermatomyositis had higher values for basal insulinemia, insulin resistance, body mass index and waist circumference. Moreover, HOMA2-IR moderately correlated with these anthropometric parameters. These metabolic abnormalities are related to the development of metabolic syndrome, one of the main comorbidities observed in dermatomyositis.

KEYWORDS: Glucose; insulin resistance; dermatomyositis; metabolic syndrome; myositis.

Oliveira DS, Guimarães MS, Shinjo SK. Insulin resistance is increased in adult patients with dermatomyositis. *MedicalExpress* (São Paulo, online). 2018;5:mo18003

Received for Publication on March 4, 2018; First review on March 31, 2018; Accepted for publication on April 10, 2018; Online on May 20, 2018
E-mail: diegosales@usp.br

INTRODUCTION

Dermatomyositis (DM) is a systemic autoimmune myopathy subtype associated with high morbidity and mortality. Clinical manifestations include symmetrical muscle weakness of limbs and cutaneous lesions, including heliotrope rash and Gottron's papules.¹⁻⁴ Moreover, extra-skeletal manifestations can also occur such as joint, pulmonary, gastrointestinal and/or cardiorespiratory involvement.²⁻⁴

Recent studies have shown a high prevalence of metabolic syndrome⁵⁻⁸ and basal insulinemia^{5,6} in systemic autoimmune myopathies. However, these parameters were assessed in patients with different glucocorticoid regimens. Since high serum levels of

insulin are associated with resistance to the action of this hormone,⁹ it is important to evaluate whether, as in other autoimmune diseases, patients with DM have increased insulin resistance and whether this parameter is associated with clinical manifestations of the disease.

The homeostatic model assessment of insulin resistance (HOMA-IR) is a mathematical model used to assess insulin resistance based on basal glycaemia and insulin.¹⁰ This method is straightforward and affordable for use in routine clinical practice. Recently, the model was updated (HOMA2-IR) providing a more accurate index.¹¹ However, to our knowledge, no studies evaluating the potential of HOMA2-IR for identifying insulin resistance in DM patients have been reported.

Therefore, the objective of this study was to evaluate insulin resistance using the HOMA2-IR model in DM patients without glucocorticoid therapy regimens.

DOI: 10.5935/MedicalExpress.2018.mo.003



Copyright © 2016 MEDICALEXPRESS. This is an open access article distributed under the terms of the creative commons attribution Non-Commercial License (creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non commercial use, distribution and reproduction in any medium, provided the original work is properly cited.

■ MATERIALS AND METHODS

This cross-sectional study was performed at a single center and initially included 71 consecutive patients with DM (age \geq 18 years) enrolled between January 2012 and July 2016 who fulfilled all of the Bohan and Peter criteria items¹ and were regularly followed at our Myopathy Unit.

As inclusion criteria, only patients who were glucocorticoid naïve or not in use of the medication for the last 3 months were included in the present study. Patients with clinically amyopathic DM, cancer-associated myositis, acute and/or chronic infections, liver and renal diseases, hypothyroidism, diabetes mellitus, in use of antimalarial drugs or statins were excluded. Therefore, 25 out of the initial 71 patients with DM were included in the study along with 50 volunteers matched for age, gender, ethnicity, weight and height, selected in the same period.

The study was approved by the institutional Ethics Committee (case # 01445312.3.0000.0068).

All participants underwent a clinical evaluation that included a standardized interview, and charts, which were extensively reviewed.

Demographic data included current age, age at disease onset, gender, ethnicity, disease duration, waist circumference, weight, height and body mass index (BMI: weight/height² - kg/m²). Clinical data included cutaneous manifestations, such as heliotrope rash, Gottron's papules, Raynaud's phenomenon, "V-neck" sign, facial rash, vasculitis, ulcers, "shawl" sign and calcinosis. Comorbidities and lifestyle evaluation, such as systemic arterial hypertension and tobacco use were also recorded.

Laboratory evaluation. A blood sample (15 mL) obtained from each participant after a 12-hour overnight fast was collected and immediately ($<$ 30 min) centrifuged at 3000 rpm for 10 minutes at 4°C, and processed. The following laboratory data were analyzed: serum levels of creatine phosphokinase (reference value: 26 - 192 U/L), aldolase (\leq 7.6 U/L), alanine aminotransferase ($<$ 31 U/L), aspartate aminotransferase ($<$ 31 U/L), lactate dehydrogenase (135 - 214 U/L), fasting blood glucose (\leq 100 mg/dL) and insulin (\leq 25 μ U/mL). Insulin resistance was defined by the HOMA2-IR model.^{11,12} Antinuclear antibodies were detected by indirect immunofluorescence using HEp-2 cells as substrate. Anti-Mi-2 autoantibody was determined using a commercial kit (Myositis Profile 3, Euroimmun, Germany) according to the manufacturer's protocol. The evaluation of the anti-Mi-2 results was based on the methods established in a previous study.¹³

Disease status. Was evaluated by the following questionnaires and scores: global assessment of the disease (by physician and patient) using the visual analogue scale (VAS),¹⁴ Manual Muscle Testing (MMT-8)¹⁵ Health Assessment Quality (HAQ)¹⁶ and Myositis Disease Activity Assessment Visual Analogue Scales (MYOACT).¹⁷ Therapy data included the use of immunosuppressive drugs.

Statistical analysis. The Kolmogorov-Smirnov test was used to evaluate the distribution of each parameter. Data were expressed as mean \pm standard deviation (SD) for continuous variables or as frequencies and percentages (%) for categorical variables. The median (25th - 75th interquartile range) was calculated for continuous variables that were non-normally distributed. Comparisons between patient vs. control parameters were made using Student's *t*-test or the Mann-Whitney test for continuous variables; the Chi-squared test or Fisher's exact test were used to evaluate the categorical variables. Correlations among the parameters were analyzed by Spearman correlation. All of the analyses were performed using the SPSS 15.0 statistics software (Chicago, USA). A value of $P < 0.05$ was considered to indicate statistical significance.

■ RESULTS

Twenty-five DM patients and 50 healthy controls were evaluated; controls were matched to patients for mean age, ethnicity, gender, weight and height distribution and thus were comparable between the two groups (Table 1). Mean age at disease onset was 40.7 years, with a median period of symptoms prior to diagnosis of 4 months.

Concerning anthropometric parameters, BMI and waist circumference were higher in DM patients compared to controls.

The main cutaneous involvement was heliotrope rash followed by: Gottron's papules, Raynaud's phenomenon, "V-neck" sign, facial rash, vasculitis, ulcers and "shawl" sign. There were no cases with calcinosis.

In general, the patients included in the present study had low disease activity, with median MMT-8 of 80, HAQ of 0.00, patient VAS of 1.0 cm, physician VAS of 0.0 cm, MYOACT of 0.4 and low serum level of muscle enzymes.

The presence of antinuclear and anti-Mi-2 antibodies was 60.0 and 12.0%, respectively.

There was no difference between groups regarding systemic arterial pressure or tobacco use.

Nine patients (36.0%) were using immunosuppressive azathioprine: 2 - 3 mg/kg/day and/or methotrexate: (15 - 20 mg/week) as monotherapy or in combination.

Higher serum levels of insulin and HOMA2-IR were observed in DM patients, compared to controls, with similar levels of glucose.

Further analysis of DM patients revealed that the HOMA2-IR was moderately correlated with weight, BMI and waist circumference (Figure 1).

■ DISCUSSION

The present study showed that the patients with DM had higher values of insulinemia and insulin resistance compared to healthy individuals. Moreover, analyzing

Table 1. General features of patients with dermatomyositis and healthy controls.

Parameters	DM (n = 25)	Control (n = 50)	P value
Current age (years)	43.5±15.2	43.4±11.2	0.968
White ethnicity	16 (64.0)	32 (64.0)	>0.999
Female gender	19 (76.0)	38 (76.0)	>0.999
Age at disease onset (years)	40.7±15.2	-	-
Duration: diagnosis - symptoms (months)	4.0 (2.3-7.8)	-	-
Anthropometric parameters			
Weight (kg)	76 (65-87)	66 (58-74)	0.087
Height (cm)	162 (158-168)	165 (157-168)	0.408
BMI (kg/cm ²)	28.9 (23.5-32.0)	24.2 (23.5-26.2)	0.037
Waist circumference (cm)	99.5 (85.0-107.0)	82.0 (78.0-90.0)	0.003
Cutaneous involvement			
Heliotrope rash	23 (93.0)	-	-
Gottron's papules	23 (92.0)	-	-
Raynaud' phenomenon	12 (48.0)	-	-
"V-neck" sign	9 (36.0)	-	-
Facial rash	15 (20.0)	-	-
Vasculitis	5 (20.0)	-	-
Ulcers	4 (16.0)	-	-
"Shawl" sign	3 (12.0)	-	-
Calcinosis	0	-	-
MMT-8 (0-80)	80 (74-80)	-	-
HAQ (0.00-3.00)	0.00 (0.00-0.43)	-	-
Patient VAS (0-10 mm)	1.0 (0.0-5.0)	-	-
Physician VAS (0-10 mm)	0.0 (0.0-3.5)	-	-
MYOACT (0-70)	0.4 (0.0-2.0)	-	-
Creatine phosphokinase (U/L)	155 (74-402)	100 (72-146)	0.041
Aldolase (U/L)	5.1 (3.6-6.8)	3.6 (2.8-4.4)	<0.001
Lactic dehydrogenase (U/L)	400 (333-596)	359 (318-400)	0.036
Alanine aminotransferase (U/L)	22 (15-52)	16 (13-21)	0.003
Aspartate aminotransferase (U/L)	26 (19-43)	20 (17-23)	0.020
Antinuclear antibody	15 (60.0)	-	-
Anti-Mi-2 antibody	3 (12.0)	-	-
Systemic arterial hypertension	8 (32.0)	8 (16.0)	0.139
Tobacco use	2 (8.0)	9 (18.0)	0.318
Glucocorticoid	0	0	>0.999
Immunosuppressive	9 (36.0)	0	-
Glucose (mg/dL)	85 (78-94)	80 (70-89)	0.084
Insulin (µU/mL)	11.4 (7.8-18.8)	6.4 (5.0-8.0)	<0.001
HOMA2-IR	2.35 (1.38-4.33)	1.20 (0.90-1.70)	<0.001

Results expressed as mean ± standard deviation, median (25th - 75th interquartile range) or percentage (%).

DM: Dermatomyositis; BMI: Body Mass Index; HAQ: Health Assessment Questionnaire; HOMA2-IR: Updated version of Homeostatic Model Assessment of Insulin Resistance; MMT: Manual Muscle Testing; MYOACT: Myositis Disease Activity Assessment Visual Analogue Scales; VAS: Visual Analogue Scales.

Immunosuppressive agents: azathioprine (2 - 3 mg/kg/day) and/or methotrexate (15 - 20 mg/week).




Figure 1. Correlation of HOMA2-IR with weight, body mass index (BMI) and waist circumference in patients with dermatomyositis. HOMA2-IR: Updated version of Homeostatic Model Assessment of Insulin Resistance; BMI: Body Mass Index.

patients with DM alone, the HOMA2-IR correlated significantly with weight, BMI and waist circumference.

Previous studies have shown a high prevalence of metabolic syndrome and basal insulinemia in DM.^{5,6} However, these parameters were assessed in the patients with different glucocorticoid therapy regimens. By contrast, the present study included only patients who were glucocorticoid naïve, or not in use of the medication for the last 3 months.

Insulin resistance is highly prevalent in autoimmune rheumatic diseases.¹⁷⁻²¹ Waist circumference, BMI and obesity seem to be the main factors contributing to increased insulin resistance in these diseases.^{22,23} For instance, BMI and waist circumference were found to be significantly associated with the HOMA2-IR in systemic lupus erythematosus.²² In rheumatoid arthritis, obesity is the main determinant of insulin resistance, even more than the circulating pro-inflammatory cytokines levels.²³

The present study corroborates the growing body of evidence suggesting that insulin resistance in autoimmune rheumatic diseases is independent of the diseases and is, instead, caused by associated risk factors.^{22,23}

Several factors can contribute to the high BMI and waist circumference found in these patients. The use of glucocorticoids could be associated with an increase in visceral fat and waist circumference.²³ However, because patients on glucocorticoid therapy were not included in the present study, other factors may have contributed to the increased waist circumference and BMI seen in these patients.

In this scenario, patients with autoimmune rheumatic diseases show marked sedentary behavior and physical inactivity, risk factors which seem to be frequently overlooked in these patients.²⁴ This behavior, in turn, can lead to an increase in BMI and waist circumference, which further contributes to increased insulin resistance.²⁵ However, in the present study, we do not measure physical activity levels in the patients with DM, or if this outcome

correlates with IR in these patients. Thus, more studies are necessary for further extrapolations. Increased BMI and waist circumference are associated with an increase in pro-inflammatory cytokines, such as TNF- α and IL-1 β , two cytokines capable of impairing insulin signaling.²⁶⁻²⁸ Furthermore, an increase in visceral fat and waist circumference is associated with activation of toll-like receptors (TLR).²⁹ TLR signaling pathways exacerbate the pro-inflammatory response, and might contribute to the development of obesity-associated insulin resistance.^{29,30}

Recent studies have shown that metabolic syndrome is highly prevalent in patients with DM.^{5,6} Metabolic syndrome, a clinically relevant condition, is defined as the presence of at least three risk factors for cardiovascular disease, including visceral obesity, dyslipidemia, hypertension and insulin resistance, with this last factor representing a central component of this disorder.⁶

The elevated levels of insulinemia and insulin resistance found in the present study, associated with the higher prevalence of metabolic syndrome, further confirm that patients with DM have a higher cardiovascular risk, independent of disease activity. Thus, strategies capable of attenuating this outcome, and consequently lowering cardiovascular risk, should be employed in this group of patients.

The present study has some limitations. A complementary analysis of the lipid profile, of acute reactant factors and also of some pro-inflammatory serum cytokines were not performed.

■ SUMMARY

Patients with DM show higher values of basal insulinemia and insulin resistance. Moreover, the HOMA2-IR correlates with weight, BMI and waist circumference in DM. These metabolic abnormalities are related to the development of metabolic syndrome, one of the main comorbidities observed in dermatomyositis.

■ AUTHOR CONTRIBUTION

D S Oliveira: reviewing literature, executing and writing the present article.

M G Silva: reviewing literature, executing and writing the present article.

S K Shinjo: planning, reviewing literature, executing and writing the present article.

■ CONFLICT OF INTEREST

All authors declare no conflict of interest.

■ ACKNOWLEDGEMENTS

This work was supported by: Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) [#2016/19771-5] to D.S.O; Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) to M.G.S; FAPESP [#2012/07101-4], Federico Foundation and Fundação Faculdade de Medicina to S.K.S.

RESISTÊNCIA INSULÍNICA AUMENTADA EM PACIENTES COM DERMATOMIOSITE

OBJETIVO: Avaliar a insulinemia em pacientes com dermatomiosite virgens de glicocorticoide e avaliar a resistência insulínica, utilizando o modelo de avaliação da homeostase de resistência insulínica (HOMA2-IR).

MÉTODOS: Este estudo transversal incluiu 25 pacientes com dermatomiosites, não-diabéticos e sem uso prévio de glicocorticoides. Para o grupo de controle, 50 voluntários foram pareados por idade, gênero, etnia, peso e estatura. O índice HOMA2-IR foi calculado a partir de dados basais de insulina e glicose. Os parâmetros do International Myositis Assessment & Clinical Studies Group (IMACS) foram utilizados para avaliar o status da doença.

RESULTADOS: A média de idade dos pacientes foi de 43,5 anos, predominantemente do sexo feminino. Os pacientes apresentaram baixa atividade de doença de acordo com os parâmetros do IMACS. O índice de massa corporal e a circunferência da cintura foram maiores no grupo da dermatomiosite em comparação com o grupo controle. O nível de insulina e o HOMA2-IR também foram maiores em pacientes com dermatomiosite. Além disso, analisando a dermatomiosite isoladamente, o índice HOMA2-IR correlacionou-se positivamente com o peso, o índice de massa corporal e a circunferência da cintura e foi independente dos parâmetros de status da doença.

CONCLUSÕES: Pacientes com dermatomiosite apresentam valores mais elevados de insulinemia basal, resistência à insulina, índice de massa corporal e circunferência da cintura. Além disso, o HOMA2-IR está

moderadamente correlacionado com esses parâmetros antropométricos. Essas anormalidades metabólicas estão relacionadas ao desenvolvimento da síndrome metabólica, uma das principais comorbidades observadas na dermatomiosite.

PALAVRAS-CHAVE: Glicose; resistência a insulina; dermatomiosite; síndrome metabólica; miosite.

■ REFERENCES

1. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). *N Engl J Med.* 1975;292(7);344-7. DOI:10.1056/NEJM197502132920706
2. Dalakas MC. Inflammatory muscle diseases. *N Engl J Med.* 2015;373(4):393-4. DOI:10.1056/NEJM197502132920706
3. Dalakas MC. Pathogenesis and therapies of immune-mediated myopathies. *Autoimmun Rev.* 2012;11(3):203-6. DOI:10.1016/j.autrev.2011.05.013
4. De Souza FHC, De Moraes TB, Levy-Neto M, Shinjo SK. Adult dermatomyositis: experience of a Brazilian tertiary care center. *Rev Bras Reumatol.* 2012;52(6):897-902. DOI:10.1590/S0482-50042012000600008
5. de Moraes MT, de Souza FH, de Barros TB, Shinjo SK. Analysis of metabolic syndrome in adult dermatomyositis with a focus on cardiovascular disease. *Arthritis Care Res (Hoboken).* 2013;65(5):793-9. DOI:10.1002/acr.21879.
6. Silva MG, Borba EF, Mello SB, Shinjo SK. Serum adipocytokine profile and metabolic syndrome in young adult female dermatomyositis patients. *Clinics (Sao Paulo).* 2016;71(12):709-14. DOI:10.6061/clinics/2016(12)06
7. de Souza FH, Shinjo SK. The high prevalence of metabolic syndrome in polymyositis. *Clin Exp Rheumatol.* 2014;32(1):82-7.
8. Araujo PAO, Silva MG, Borba EF, Shinjo SK. High prevalence of metabolic syndrome in antisynthetase syndrome. *Clin Exp Rheumatol.* 2017 (accepted).
9. Zhang X, Li J, Zheng S, Luo Q, Zhou C, Wang C. Fasting insulin, insulin resistance, and risk of cardiovascular or all-cause mortality in non-diabetic adults: a meta-analysis. *Biosci Rep.* 2017;37(5):pii:BSR20170947. DOI:10.1042/BSR20170947
10. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia.* 1985;28(7):412-9.
11. Levy JC, Matthews DR, Hermans MP. Correct homeostasis model assessment (HOMA) evaluation uses the computer program. *Diabetes Care.* 1998;21(12):2191-2.
12. Nolan JJ, Faerch K. Estimating insulin sensitivity and beta cell function: perspectives from the modern pandemics of obesity and type 2 diabetes. *Diabetologia.* 2012;55(11):2863-7. DOI:10.1007/s00125-012-2684-0
13. Cruellas MG, Viana V dos S, Levy-Neto M, Souza FH, Shinjo SK. Myositis-specific and myositis-associated autoantibody profiles and their clinical associations in a large series of patients with polymyositis and dermatomyositis. *Clinics (Sao Paulo).* 2013;68(7):909-14. DOI:10.6061/clinics/2013(07)04
14. Miller FW, Rider GL, Chung YL, Cooper R, Danko K, Farewell V, et al. Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. *Rheumatology (Oxford).* 2001;40(11):1262-73. DOI:10.1093/rheumatology/40.11.1262
15. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European

- and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. *Eur Heart J*. 2003;24(17):1601-10.
16. Bruce B, Fries JF. The Stanford Health Assessment Questionnaire: dimensions and practical applications. *Health Qual Life Outcomes*. 2003; 1:20. DOI:10.1186/1477-7525-1-20
 17. Rider LG, Giannini EH, Harris-Love M, Joe G, Isenberg D, Pilkington C, et al. Defining clinical improvement in adult and juvenile myositis. *J Rheumatol*. 2003;30(3):603-17.
 18. Kang Y, Park HJ, Kang MI, Lee HS, Lee SW, Lee SK, et al. Adipokines, inflammation, insulin resistance, and carotid atherosclerosis in patients with rheumatoid arthritis. *Arthritis Res Ther*. 2013;15:194-201. DOI:10.1186/ar4384
 19. Miyake CN, Gualano B, Dantas WS, Pereira RT, Neves W, Zambelli VO, et al. Increased insulin resistance and glucagon levels in mild/inactive systemic lupus patients despite normal glucose tolerance. *Arthritis Care Res (Hoboken)*. 2018;70(1):114-124. DOI:10.1002/acr.23237
 20. Sánchez-Pérez H, Tejera-Segura B, de Vera-González A, González-Delgado A, Olmos JM, Hernández JL, et al. Insulin resistance in systemic lupus erythematosus patients: contributing factors and relationship with subclinical atherosclerosis. *Clin Exp Rheumatol*. 2017;35(6):885-92.
 21. Pereira RM, de Carvalho JF, Bonfá E. Metabolic syndrome in rheumatological diseases. *Autoimmun Rev*. 2009;8(5):415-9. DOI:10.1016/j.autrev.2009.01.001
 22. Castillo-Hernandez J, Maldonado-Cervantes MI, Reyes JP, Patiño-Marin N, Maldonado-Cervantes E, Solorzano-Rodríguez C, et al. Obesity is the main determinant of insulin resistance more than the circulating pro-inflammatory cytokines levels in rheumatoid arthritis patients. *Rev Bras Reumatol*. 2017;57(4):320-9. DOI:10.1016/j.rbre.2017.01.008
 23. Wang M. The role of glucocorticoid action in the pathophysiology of the Metabolic Syndrome. *Nutr Metab (Lond)*. 2005;2:3-17. DOI:10.1186/1743-7075-2-3
 24. Pinto AJ, Roschel H, de Sá Pinto AL, Lima FR, Pereira RMR, Silva CA, et al. Physical inactivity and sedentary behavior: Overlooked risk factors in autoimmune rheumatic diseases? *Autoimmun Rev*. 2017;16(7):667-674. DOI:10.1016/j.autrev.2017.05.001.
 25. Scheuer SH, Færch K, Philipsen A, Jørgensen ME, Johansen NB, Carstensen B, et al. Abdominal Fat Distribution and Cardiovascular Risk in Men and Women With Different Levels of Glucose Tolerance. *J Clin Endocrinol Metab*. 2015;100(9):3340-7. DOI:10.1210/JC.2014-4479.
 26. Stgakis I, Bertias G, Karvounaris S, Kavousanaki M, Virla D, Raptopoulou A, et al. Anti-tumor necrosis factor therapy improves insulin resistance, beta cell function and insulin signaling in active rheumatoid arthritis patients with high insulin resistance. *Arthritis Res Ther*. 2012;14(3):R141-52. DOI:10.1186/ar3874.
 27. Cao H. Adipocytokines in obesity and metabolic disease. *J Endocrinol*. 2014;220(2):T47-59. DOI:10.1530/JOE-13-0339.
 28. Gao D, Madi M, Ding C, Fok M, Steele T, Ford C, et al. Interleukin-1 β mediates macrophage-induced impairment of insulin signaling in human primary adipocytes. *Am J Physiol Endocrinol Metab*. 2014;307(3):E289-304. DOI:10.1152/ajpendo.00430.2013.
 29. Eguchi K, Manabe I. Toll-like receptor, lipotoxicity and chronic inflammation: the pathological link between obesity and cardiometabolic disease. *J Atheroscler Thromb*. 2014;21(7):629-39.
 30. Johnson AR, Milner JJ, Makowski L. The inflammation highway: metabolism accelerates inflammatory traffic in obesity. *Immunol Rev*. 2012;249(1):218-38. DOI:10.1111/j.1600-065X.2012.01151.x